

## CLAIMS

What is claimed is:

1. A method of treating neurodegenerative inflammation in a human in need thereof,  
5 comprising administering to the cerebrospinal fluid (CSF) of said human an effective TNF-inhibiting amount of an anti-TNF antibody or TNF binding fragment thereof sufficient to treat the neurodegenerative inflammation.
2. A method of treating neurodegenerative inflammation in a human in need thereof,  
10 comprising administering to the cerebrospinal fluid (CSF) of said human an effective TNF-inhibiting amount of an anti-TNF antibody or TNF binding fragment thereof sufficient to treat the neurodegenerative inflammation, wherein said anti-TNF antibody or fragment is a chimeric TNF antibody.
3. A method of treating neurodegenerative inflammation in a human in need thereof,  
15 comprising administering to the cerebrospinal fluid (CSF) of said human an effective TNF-inhibiting amount of an anti-TNF antibody or TNF binding fragment thereof sufficient to treat the neurodegenerative inflammation, wherein said anti-TNF antibody or fragment competitively inhibits the binding of TNF to the TNF antibody cA2 .
4. The method of Claim 3, wherein the chimeric TNF antibody comprises non-  
20 human variable region.
5. The method of Claim 1, wherein said administration comprises a single or divided 0.1 - 100 mg/kg dose of said anti-TNF antibody or fragment thereof.

6. The method of Claim 2, wherein said administration comprises a single or divided 0.1 - 100 mg/kg dose of said anti-TNF antibody or fragment thereof.
7. The method of Claim 3, wherein said administration comprises a single or divided 0.1 - 100 mg/kg dose of said anti-TNF antibody or fragment thereof.
- 5 8. The method of Claim 1 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: disease-modifying anti-rheumatic drugs, anti-inflammatory agents, anti-neoplastic agents, radionuclides, radiotherapeutics, immunosuppressives, cytotoxic drugs, monoclonal antibodies, murine antibodies, chimeric antibodies, antibody  
10 fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.
9. The method of Claim 2 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: disease-modifying anti-rheumatic drugs, anti-inflammatory agents, anti-neoplastic  
15 agents, radionuclides, radiotherapeutics, immunosuppressives, cytotoxic drugs, monoclonal antibodies, murine antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.
10. The method of Claim 3 further comprising administering to the human an  
20 effective amount of a therapeutic agent selected from the group consisting of: disease-modifying anti-rheumatic drugs, anti-inflammatory agents, anti-neoplastic agents, radionuclides, radiotherapeutics, immunosuppressives, cytotoxic drugs,

-157-

monoclonal antibodies, murine antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.

11. The method of Claim 8, wherein the therapeutic agent is a disease-modifying anti-rheumatic drug.
12. The method of Claim 11, wherein the disease-modifying anti-rheumatic drug is selected from the group consisting of: auranofin, azathioprine, chloroquine, D-penicillamine, gold sodium thiomalate hydroxychloroquine, Myocrisin and sulfasalazine methotrexate.
13. The method of Claim 8, wherein the therapeutic agent is an anti-inflammatory agent.
14. The method of Claim 13, wherein the anti-inflammatory agent is selected from the group consisting of: pentasa, mesalazine, asacol, codeine phosphate, benorylate, fenbufen, naprosyn, diclofenac, etodolac and indomethacin, aspirin and ibuprofen.
15. The method of Claim 8, wherein the therapeutic agent is a pain control agent.
16. The method of Claim 15, wherein the pain control agent is selected from the group consisting of: paracetamol and dextropropoxyphene.

-158-

17. The method of Claim 1 further comprising administering to the human an effective amount of at least one therapeutic agent selected from the group consisting of: at least one antibiotic and at least one steroid.
18. The method of Claim 1, wherein the anti-TNF chimeric antibody is of immunoglobulin class IgG1, IgG2, IgG3, IgG4 or IgM.
19. The method of Claim 1, wherein the anti-TNF chimeric antibody is a fragment selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub> and Fv.